Results 51 to 60 of about 572,501 (357)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Detection of genome-wide methylation changes in bladder cancer by long-read sequencing of urinary DNA

Clinical Epigenetics
Background Non-invasive urine tests for bladder cancer (BC) could reduce dependence on flexible cystoscopy for diagnosis and surveillance. Most recent developments in urine testing are based on targeted detection of genomic and/or epigenomic markers.
Anshita Goel, Benjamin J. Tura, Joanne D. Stockton, Nicholas Tovey, Luke Ames, Andrew D. Beggs, Maurice P. Zeegers, Nicholas D. James, K. K. Cheng, Richard T. Bryan, Douglas G. Ward, Roland Arnold   +11 more
doaj   +1 more source

Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors [PDF]

, 2018
To compare long-term overall survival (OS) in patients with G1 and G2 grade Ta bladder cancer after transurethral resection of bladder tumors (TURBTs).
Balan, Daniel, Borda, Angela, Busetto, Gian Maria, Chibelean, Calin Bogdan, Cioffi, Antonio, De Berardinis, Ettore, Del Giudice, Francesco, Ferro, Matteo, Lucarelli, Giuseppe, Martha, Orsolya, Matei, Victor Deliu, Porav-Hodade, Daniel, Pytel, Akos, Sin, Anca, Tataru, Sabin, Vartolomei, Mihai Dorin, Voidezan, Septimiu   +16 more
core   +2 more sources

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy

Bladder Cancer, 2017
Objective: Urothelial prostatic involvement (UPI) at the time of radical cystoprostatectomy (RCP) was found associated with worse survival outcomes by several previous reports.
Marco Moschini, Francesco Soria, Martin Susani, Stephan Korn, Alberto Briganti, Morgan Roupret, Christian Seitz, Killian Gust, Andrea Haitel, Francesco Montorsi, Gregory Wirth, Brian D. Robinson, Pierre I. Karakiewicz, Mehmet Özsoy, Michael Rink, Shahrokh F. Shariat   +15 more
doaj   +1 more source

Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery [PDF]

, 2011
Objective: The aim of this study was to externally validate the prognostic value of concomitant urothelial carcinoma in situ (CIS) in radical cystectomy (RC) specimens using a large international cohort of bladder cancer patients. Methods: The records of
Colin P. Dinney, Derya Tilki, Eila Skinner, Francesco Montorsi, Giacomo Novara, Guru Sonpavde, Habuchi T, Hans-Martin Fritsche, Hendrik Isbarn, Jonathan I. Izawa, Knowles MA, Lamm DL, Patrick J. Bastian, Philipp Nuhn, Pierre I. Karakiewicz, Robert S. Svatek, Rosin MP, Sarkis AS, Shahrokh F. Shariat, Skinner DG, Spruck, Stefan C. Müller, Utz DC, Vincenzo Ficarra, Wassim Kassouf, Yves Fradet, Zincke H   +26 more
core   +1 more source

COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype [PDF]

, 2023
K. B. Kim, Young Joon Byun, Chuang-Ming Zheng, Sungmin Moon, Soo Jeong Jo, Ho Won Kang, Won Tae Kim, Yung Hyun Choi, Sung‐Kwon Moon, Wun‐Jae Kim, Xuan‐Mei Piao, Seok Joong Yun   +11 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience

Frontiers in Oncology
IntroductionEnfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4.
Evangelia Vlachou, Evangelia Vlachou, Burles Avner Johnson, Burles Avner Johnson, David McConkey, David McConkey, Yuezhou Jing, Andres Matoso, Andres Matoso, Andres Matoso, Andres Matoso, Noah M. Hahn, Noah M. Hahn, Noah M. Hahn, Jean Hoffman-Censits, Jean Hoffman-Censits, Jean Hoffman-Censits   +16 more
doaj   +1 more source